Drug Profile
Zolbetuximab - Astellas Pharma
Alternative Names: Anti-claudin 18.2 antibody - Astellas Pharma; Chimeric monoclonal antibody against claudin-18 splice variant 2 - Astellas Pharma; Claudiximab - Astellas Pharma; IMAB-362; VYLOYLatest Information Update: 04 Apr 2024
Price :
$50
*
At a glance
- Originator Ganymed Pharmaceuticals
- Developer Astellas Pharma; Ganymed Pharmaceuticals
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Gastric cancer
- Preregistration Oesophageal cancer
- Phase II Pancreatic cancer
Most Recent Events
- 04 Apr 2024 Astellas Pharma anticipates approval of zolbetuximab for Gastric and Oesophageal cancer in China (IV) in the fourth quarter of 2024
- 04 Apr 2024 Astellas Pharma anticipates approval of zolbetuximab for Gastric and Oesophageal cancer in the US (IV) in the second or third quarter of 2024
- 26 Mar 2024 Registered for Gastric cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent) in Japan (IV) - First global approval